News and Announcements
Fuel Sector Investment Strategies Explained: Peter Rossi on Chevron-Backed Trusts & 12.25% Returns
- Published October 15, 2024 7:39AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Peter Rossi from Amplify Funds Management explains the innovative strategies behind their Fuel and Convenience Trust, which delivers a 12.25% annual return. Learn how Chevron-backed assets provide security and why electric vehicles aren’t a concern for Amplify’s rural and industrial-focused portfolio. Rossi also discusses the rise of convenience store sales and the role they play in the future of the fuel industry. Watch now to gain valuable insights into smart investment strategies in the fuel and convenience sector.
Executive Interviews
12.25% Total Returns? This Trust’s Fuel and Convenience Strategy Is Pumping Up Profits
The Queensland Property Strategy Turning Heads—And Profits In the world of commercial property investment, finding the next big opportunity is like striking gold. And right now, there’s a gold rush happening in Queensland, with Amplify, a Queensland-based Funds Manager, leading the charge. Let’s cut through the noise and see what’s really going on. The Amplify […]
A Nation Divided: Insights from Our Subscriber Poll on the Upcoming U.S. Election
October 20, 2024 This entire post was created by ChatGPT o1 utilising the data and comments from the poll. The world watches closely as the United States stands on the brink of a consequential presidential election. The outcome will shape America’s future and have profound implications for the global economy and international relations. To capture […]
A New Era of Investment in Australia’s Life Science Sector
In just six months, four new investment funds have emerged, all targeting Australia’s life sciences and healthcare companies. With scientific advancements, government backing, and structural undervaluation, these funds represent a significant moment for the sector—offering investors a rare opportunity to capitalise on growth in biotech and medtech.
Backed By Leading Investment Groups and Family Offices
